KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells $2,960,232.75 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the sale, the insider owned 5,129,340 shares in the company, valued at $86,942,313. The trade was a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, March 26th, Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08.

KalVista Pharmaceuticals Trading Down 5.0%

Shares of KALV stock opened at $18.36 on Tuesday. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.95. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The firm has a market capitalization of $940.40 million, a PE ratio of -4.65 and a beta of -0.35. The stock has a fifty day simple moving average of $16.12 and a two-hundred day simple moving average of $14.47.

Analysts Set New Price Targets

Several analysts recently issued reports on KALV shares. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Wall Street Zen upgraded KalVista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC increased their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Citizens Jmp lowered their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $32.60.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several large investors have recently made changes to their positions in KALV. Tudor Investment Corp ET AL bought a new position in KalVista Pharmaceuticals during the third quarter valued at approximately $24,360,000. Vestal Point Capital LP grew its holdings in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after acquiring an additional 905,053 shares in the last quarter. Finally, Elmind Capital LP purchased a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $12,941,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.